That's a great question! Mosunetuzumab (Lunsumio) is an FDA-approved treatment for adults with relapsed or refractory follicular lymphoma who have already tried at least two other systemic therapies.
While there aren't specific MyLymphomaTeam member experiences to share here right now, it may be worth bringing up with your Show Full Answer
That's a great question! Mosunetuzumab (Lunsumio) is an FDA-approved treatment for adults with relapsed or refractory follicular lymphoma who have already tried at least two other systemic therapies.
While there aren't specific MyLymphomaTeam member experiences to share here right now, it may be worth bringing up with your care team to see if it could be a fit for your situation.
Here are some key things to know about Mosunetuzumab:
- It's a bispecific antibody, meaning it targets two things at once — it helps your immune system's T cells find and destroy lymphoma cells
- It's given intravenously (by IV)
- It's specifically approved for follicular lymphoma that has come back or stopped responding to previous treatments As with any treatment, there are potential risks and side effects to be aware of, so a thorough conversation with your oncologist is really important before starting. They can help weigh the benefits against any risks based on your specific health history.
Connecting with others on MyLymphomaTeam who may have firsthand experience with this treatment could also be really valuable!
June 15
Join
Your Privacy Choices
